Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Ward T. Smith"'
Autor:
Ward T. Smith, Lynn Cunningham, Joseph P. Horrigan, Peter D. Londborg, Robert J. Bielski, Kenneth J. Weiss
Publikováno v:
The Journal of Clinical Psychiatry. 69:571-577
Objective To evaluate the efficacy and tolerability of extended-release gepirone (gepirone-ER), a 5-HT(1A) agonist, versus placebo in the treatment of adult outpatients with major depressive disorder (MDD). Method A double-blind, randomized, placebo-
Autor:
David L. Dunner, Kirsten L. Haman, Mark Hyman Rapaport, John Zajecka, Ward T. Smith, Robert M. A. Hirschfeld, Ari Kiev, R. Bruce Lydiard, Richard C. Shelton
Publikováno v:
The Journal of Clinical Psychiatry. 67:1674-1681
Objective Sertraline may produce dual neurotransmitter effects similar to the serotonin-norepinephrine reuptake inhibitors (SNRIs); however, it has been tested against an SNRI in only 1 previous study, and never at an optimal dose. The objective of t
Autor:
Alan D. Feiger, Ward T. Smith, Jon F. Heiser, Ram K. Shrivastava, Michael Gibertini, J M A Sitsen, Kenneth J. Weiss
Publikováno v:
The Journal of Clinical Psychiatry. 64:243-249
OBJECTIVE To assess the efficacy and tolerability of the 5-HT(1A) agonist gepirone in extended-release formulation (gepirone-ER) versus placebo in patients with major depressive disorder. METHOD Patients aged 18 to 70 years were eligible if they sati
Autor:
Carol A. Janney, Peter D. Londborg, Dan L. Zimbroff, Maria Liu-Dumaw, Douglas Feltner, Richard H. Weisler, Atul C. Pande, Jonathan R. T. Davidson, Jerri G. Crockatt, Ward T. Smith, Robert J. Bielski
Publikováno v:
American Journal of Psychiatry. 160:533-540
Current drug therapies for generalized anxiety disorder have limitations. In a controlled trial, the novel agent pregabalin was studied for the treatment of patients with generalized anxiety disorder.In this double-blind study, patients with DSM-IV g
Publikováno v:
American Journal of Psychiatry. 155:1339-1345
Objective: Because selective serotonin reuptake inhibitors (SSRIs) require 2‐4 weeks to reach efficacy, the authors determined whether clonazepam augmentation of fluoxetine is superior to fluoxetine alone at the beginning of treatment for major dep
Autor:
Fumisuke Matsuo, Hugh C. Hendrie, Robert L. Herting, John J. Sramek, Neal R. Cutler, Ward T. Smith, T. Daniel Fakouhi
Publikováno v:
Journal of Geriatric Psychiatry and Neurology. 6:115-119
A multicenter, double-blind, placebo-controlled, parallel group study was conducted to assess the safety and efficacy of three doses of milacemide in the treatment of patients with senile dementia of the Alzheimer type of mild to moderate severity. P
Autor:
Maurizio Fava, Victoria Ameral, Peter D. Londborg, Lee Baer, Alisabet Clain, Vincent Glaudin, Ward T. Smith, Carrie E. Brintz, George I. Papakostas, John R. Painter
Publikováno v:
International clinical psychopharmacology. 25(1)
Anxious depression, defined as major depressive disorder (MDD) accompanied by high levels of anxiety, seems to be both common and difficult to treat, with antidepressant monotherapy often yielding modest results. We sought to examine the relative ben
Autor:
Peter D. Londborg, Michael R. Liebowitz, Nicholas DeMartinis, Cathryn M. Clary, Rana Fayyad, Ward T. Smith, Karen L. Weihs, Henry Chung
Publikováno v:
The Journal of clinical psychiatry. 64(7)
BACKGROUND Generalized social anxiety disorder is an early onset, highly chronic, frequently disabling disorder with a lifetime prevalence of approximately 13%. The goal of the current study was to evaluate the efficacy and tolerability of sertraline
Autor:
Alan D, Feiger, Jon F, Heiser, Ram K, Shrivastava, Kenneth J, Weiss, Ward T, Smith, J M A, Sitsen, Michael, Gibertini
Publikováno v:
The Journal of clinical psychiatry. 64(3)
To assess the efficacy and tolerability of the 5-HT(1A) agonist gepirone in extended-release formulation (gepirone-ER) versus placebo in patients with major depressive disorder.Patients aged 18 to 70 years were eligible if they satisfied DSM-IV crite
Publikováno v:
Journal of affective disorders. 70(3)
Clonazepam cotherapy of fluoxetine was previously demonstrated to accelerate efficacy over the first 3 weeks of treatment. A new 18-week double-blind study attempted to replicate these findings to determine whether superiority would extend to 3 month